American Vietnamese Biotech (HSTC:AMV) Notes Receivable: ₫0.00 Mil (As of . 20)


What is American Vietnamese Biotech Notes Receivable?

American Vietnamese Biotech HSTC:AMV Notes Receivable is ₫0.00 Mil as of . 20.

American Vietnamese Biotech's Notes Receivable for the quarter that ended in . 20 was ₫0.00 Mil.

American Vietnamese Biotech Notes Receivable Related Terms

American Vietnamese Biotech Notes Receivable Historical Data

* Premium members only.

The historical data trend for American Vietnamese Biotech's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

American Vietnamese Biotech Notes Receivable Chart

American Vietnamese Biotech Annual Data
Trend
Notes Receivable

American Vietnamese Biotech Quarterly Data
Notes Receivable

American Vietnamese Biotech Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₫0.00 Mil mean?
American Vietnamese Biotech (HSTC:AMV) has a Notes Receivable of ₫0.00 Mil as of . 20. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on American Vietnamese Biotech and its competitors.
Is American Vietnamese Biotech's Notes Receivable too high?
American Vietnamese Biotech's current Notes Receivable is ₫0.00 Mil.
How does American Vietnamese Biotech's Notes Receivable compare to HSTC and STLT?
American Vietnamese Biotech's Notes Receivable of ₫0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on American Vietnamese Biotech and its competitors. American Vietnamese Biotech's current Notes Receivable is ₫0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is American Vietnamese Biotech stock overvalued right now?
American Vietnamese Biotech (HSTC:AMV) has a current Notes Receivable of ₫0.00 Mil. The current Notes Receivable is ₫0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For American Vietnamese Biotech (HSTC:AMV), the current Notes Receivable is ₫0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

American Vietnamese Biotech Business Description

Address No. 85 Hoang Van Thai, 4th Floor, Phu Ma Duong Building, Tan Phu Ward, District 7, Ho Chi Minh, VNM
American Vietnamese Biotech Incorporation is engaged in trading in pharmaceuticals, purchasing and selling medical equipment, medical testing instruments, and chemicals; producing and trading vaccines and medical biological products.